Lv4
460 积分 2024-09-05 加入
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
4天前
已完结
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
4天前
已关闭
International Myeloma Working Group recommendations for global myeloma care
4天前
已完结
International Myeloma Working Group recommendations for global myeloma care
4天前
已完结
Ib期TRIMM-2研究
1个月前
已完结
Ib期TRIMM-2研究
1个月前
已关闭
Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
1个月前
已关闭
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
2个月前
已完结
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
2个月前
已完结
皖公网安备34019202002308
